23ANDME HOLDING CO -CLASS A (ME)
US90138Q1085 - Common Stock
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented...
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Matterport is being acquired by a real estate giant, but it might not be the last ex-SPAC to go this route.
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Matterport is being acquired by a real estate giant, but it might not be the last ex-SPAC to go this route.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Which stocks are most active on Thursday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Thursday Sector Leaders: General Contractors & Builders, Diagnostics
Commit To Buy 23andMe Holding At $0.50, Earn 114.1% Annualized Using Options
Why Is Lithium Americas (LAC) Stock Down 28% Today?
Lithium Americas stock is falling on Thursday after the lithium mining company announced the pricing of a public offering for LAC shares.
Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts
Walgreens layoffs are in the news Thursday after the pharmacy chain announced plans to cut jobs in Chicago while reducing employees' hours.
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
23andMe stock is rallying on Wednesday after the company's CEO announced plans to take ME shares private in a potential deal.
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
23andMe Jumps as CEO Floats Plan to Take DNA Tester Private
DNA testing firm 23andMe Holding Co.’s shares soared after Chief Executive Officer Anne Wojcicki said she’s considering taking the struggling company private, less than three years after it began selling shares.
Curious about the stocks that are showing activity before the opening bell on Thursday?
Which stocks are moving before the opening bell on Thursday?
23andMe announces CEO’s intention to pursue a potential take-private
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T...
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also...
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migration
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and...
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock
Nu Holdings went from an idea to a $50 billion business over a handful of years. Several billionaire investors are betting on even more upside.
23andMe Launches New Genetic Reports on Common Forms of Cancer
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe
23andMe Launches New Genetic Reports on Common Forms of Cancer
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on...
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathway
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6...
Is 23andMe Stock a Smart Buy Right Now?
It's having trouble getting its core business model to work.
23andMe stock falls 20% amid earnings report, breakup speculation (NASDAQ:ME)
23andMe (ME) stock tumbled 20% Thursday in the wake of reports that the company might be split up and a fiscal Q3 earnings report that missed of Street estimates. Read more here.